BRCA1 and neoplasm: Of note, the presence of non-BRCA1/2 DDR mutations did not appear to enhance sensitivity to talazoparib in patients with BRCA1/2mut; this finding was expected given that patients were enrolled based on gBRCAmut status and the importance of gBRCAmut in tumor pathobiology in such patients, potentially suggesting that the observation in Cohort 2 was a chance finding.